Evaluation of akathisia in patients with schizophrenia, schizoaffective disorder, or bipolar i disorder: A post hoc analysis of pooled data from short- and long-term aripiprazole trials

John M. Kane, Thomas Re Barnes, Christoph U. Correll, Gary Sachs, Peter Buckley, James Eudicone, Robert McQuade, Quynh Van Tran, Andrei Pikalov, Sheila Assunção-Talbott

Research output: Contribution to journalArticle

47 Scopus citations

Abstract

The objective of this article is to assess the clinical characteristics of akathisia in patients with schizophrenia, schizoaffective disorder, or bipolar I disorder receiving aripiprazole, haloperidol, olanzapine, or placebo. We conducted post hoc analyses of pooled safety data from trials in patients with schizophrenia, schizoaffective disorder, and bipolar I disorder. Outcome measures included the incidence of akathisia, time to onset, duration, severity, and discontinuation due to akathisia, concomitant use of benzodiazepines and/or anticholinergics, Barnes Akathisia Rating Scale (BARS) scores, and the correlation between antipsychotic efficacy and akathisia. The results for schizophrenia and schizoaffective disorder were as follows: akathisia in 9% of aripiprazole- and 6% of placebo-treated patients; 12.5% of aripiprazole- versus 24% of haloperidol-treated patients; 11% of aripiprazole- versus 6% of olanzapine-treated patients. Bipolar I disorder: akathisia in 18% of aripiprazole- and 5% of placebo-treated patients. The clinical characteristics of akathisia were similar between each data set, regardless of disease. Akathisia was generally mild-to-moderate in severity. Discontinuation due to akathisia was low in both the schizophrenia trials (aripiprazole 0.3%; placebo 0%; aripiprazole 0.9%; haloperidol 2.3%; aripiprazole 1.2%; olanzapine 0.2%) and the bipolar trials (aripiprazole 2.3%; placebo 0%). Treatment-emergent akathisia was not associated with a poorer clinical response. In conclusion, akathisia with aripiprazole occurred early in treatment, was mild-to-moderate in severity, led to few study discontinuations, and did not compromise therapeutic efficacy.

Original languageEnglish (US)
Pages (from-to)1019-1029
Number of pages11
JournalJournal of Psychopharmacology
Volume24
Issue number7
DOIs
StatePublished - Jul 1 2010

Keywords

  • Akathisia
  • Aripiprazole
  • Bipolar I disorder
  • Haloperidol
  • Olanzapine
  • Schizoaffective disorder
  • Schizophrenia

ASJC Scopus subject areas

  • Pharmacology
  • Psychiatry and Mental health
  • Pharmacology (medical)

Fingerprint Dive into the research topics of 'Evaluation of akathisia in patients with schizophrenia, schizoaffective disorder, or bipolar i disorder: A post hoc analysis of pooled data from short- and long-term aripiprazole trials'. Together they form a unique fingerprint.

  • Cite this

    Kane, J. M., Barnes, T. R., Correll, C. U., Sachs, G., Buckley, P., Eudicone, J., McQuade, R., Tran, Q. V., Pikalov, A., & Assunção-Talbott, S. (2010). Evaluation of akathisia in patients with schizophrenia, schizoaffective disorder, or bipolar i disorder: A post hoc analysis of pooled data from short- and long-term aripiprazole trials. Journal of Psychopharmacology, 24(7), 1019-1029. https://doi.org/10.1177/0269881109348157